Trilostane Veterinary API: Effective Treatment for Canine Cushing's Syndrome and Hormone-Related Disorders
Trilostane (CAS Number: 13647-35-3) is a well-established veterinary medication primarily used for the treatment of Cushing's syndrome (hyperadrenocorticism) in dogs. Produced according to in-house quality standards, Trilostane is recognized for its targeted mechanism of action and consistent therapeutic performance in veterinary practice.
By regulating steroid hormone synthesis, Trilostane plays a vital role in managing disorders associated with excess cortisol production.
Product Overview
- Product Name: Trilostane
- CAS Number: 13647-35-3
- Standard: In-house standard
- Category: Veterinary API / Endocrine Therapy
- Primary Indication: Cushing's syndrome in dogs
Mechanism of Action
Trilostane works by inhibiting the enzyme 3β-hydroxysteroid dehydrogenase, a key enzyme involved in the synthesis of cortisol and other steroid hormones in the adrenal glands. By blocking this pathway, Trilostane effectively reduces cortisol production, helping restore hormonal balance and relieve clinical symptoms.
Applications of Trilostane
Veterinary Medicine Applications
1. Cushing's Syndrome in Dogs
Trilostane is most widely prescribed for the management of canine Cushing's syndrome, a condition characterized by chronic overproduction of cortisol. Treatment with Trilostane helps:
- Lower excessive cortisol levels
- Reduce symptoms such as excessive thirst, urination, panting, and hair loss
- Improve overall quality of life in affected dogs
Its predictable action and controllable dosing make it a preferred option in long-term disease management.
2. Adrenal Tumors in Dogs
Trilostane may also be used to manage functional adrenal tumors that result in hormone overproduction. In these cases, it can:
- Reduce excess cortisol secretion
- Alleviate hormone-related clinical symptoms
- Support medical management when surgery is not feasible
Experimental and Research Applications
1. Cancer Research
Trilostane has been investigated in experimental cancer research, particularly in hormone-dependent cancers such as breast and prostate cancer. By interfering with steroid hormone synthesis, it may help inhibit the growth of hormone-sensitive tumor cells. Further research is ongoing to clarify its clinical relevance in oncology.
2. Other Endocrine Disorders
Due to its ability to modulate steroid hormone production, Trilostane has potential research applications in other endocrine disorders, including:
- Congenital adrenal hyperplasia
- Certain forms of hyperaldosteronism
- Steroid hormone imbalance conditions
These applications remain largely investigational but highlight the compound's broader therapeutic potential.
Conclusion
Trilostane (CAS No. 13647-35-3) is a highly effective veterinary endocrine therapy, best known for its role in treating Cushing's syndrome in dogs. Its targeted inhibition of cortisol synthesis makes it a valuable and reliable option in veterinary medicine, with ongoing research exploring additional applications in endocrinology and oncology.
Hot Tags: veterinary medications cushing disease trilostane powder, China veterinary medications cushing disease trilostane powder manufacturers, suppliers, factory, Pradofloxacin, Denaverine Hydrochloride, 13647-35-3, Flumethrin, 69770-45-2, 790299-79-5
